Abbonarsi

Six-week antibiotic therapy after one-stage replacement arthroplasty for hip and knee periprosthetic joint infection - 22/09/20

Antibiothérapie de six semaines pour les infections ostéoarticulaires sur prothèse de hanche et genou après reprise totale en un temps

Doi : 10.1016/j.medmal.2020.03.003 
G. Chieffo a, b, , S. Corsia c, G. Rougereau c, M. Enser d, L.J. Eyrolle d, S. Kernéis a, P. Morand e, J. Loubinoux e, R. Gauzit d, P. Leclerc c, P. Wipff f, Y. Allanore f, P. Anract c, D. Salmon a,
a Infectious Diseases and Tropical Medicine Department, AP–HP, Cochin Hôtel-Dieu, Paris Descartes University, Paris, France 
b Infectious Diseases and Tropical Medicine Department, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy 
c Orthopedic Surgery Department, AP–HP, Cochin Hospital, Paris Descartes University, Paris, France 
d Department of Anesthesiology, Infectious Diseases Unit, AP–HP, Cochin Hospital, Paris Descartes University, Paris, France 
e Department of Bacteriology, HUPC, Cochin Hospital, Paris Descartes University, Paris, France 
f Rheumatology Department, AP–HP, Cochin Hôtel-Dieu, Paris Descartes University, Paris, France 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 8
Iconografia 1
Video 0
Altro 0

Highlights

Periprosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantations with significant morbidity and mortality.
One-stage replacement arthroplasty for the treatment of PJIs results in similar cure rate than two-stage replacement arthroplasty, but the antibiotic therapy duration is not well established.
Recent data reported successful results with a six-week antibiotic therapy for two-stage arthroplasty, while the experience is very limited for one-stage arthroplasty.
We aimed to evaluate the effectiveness of a short six-week antibiotic course in PJIs after one-stage exchange.
A six-week course of antibiotics for knee and hip PJIs treated with one-stage replacement arthroplasty had a satisfactory remission rate.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Objectives

One-stage replacement arthroplasty for treatment of periprosthetic joint infection (PJI) results in similar cure rate than two-stage (around 85–92%), but antibiotic therapy duration is not well established. The aim of this study was to evaluate the efficacy of a short six-week antibiotic course in periprosthetic joint infections after onstage exchange.

Patients and methods

Retrospective, observational study conducted at Orthopaedic Department of Cochin Hospital, Paris, between 1st January 2010 and 31 December 2015. Patients with a microbiologically proven PJI, treated with one-stage replacement and 6 weeks (+/1week) of antimicrobial therapy were included. Pearson's-χ2 and Wilcoxon tests were used to compare categorical and continuous variables.

Results

Fifty patients with periprosthetic joint infections (42 hip, 8 knee PJI) treated with one-stage replacement arthroplasty were included. Median age was 69.3 years (IQR 24.5–97.4). Infections occurred after a mean of 36 months (IQR 1–216). Bone biopsy cultures were positive for Staphylococcus spp. in 29 patients (58%), Cutibacterium acnes in 19 (38%), Gram-negative bacilli in 6 (12%). Polymicrobial infections occurred in 12 (24%). Intravenous antibiotics were administered for a median of 11 days (IQR 4–45) and 46 patients (92%) were switched to an oral therapy. Medium follow-up was of 32 months (IQR 12–101). Overall remission rate was 90%.

Conclusions

A six-week course of antibiotics in knee and hip PJIs treated with one-stage RA has a satisfactory remission rate in this open study.

Il testo completo di questo articolo è disponibile in PDF.

Résumé

Objectifs

La reprise totale de prothèse (RTP) en un temps pour le traitement des infections ostéoarticulaires (IOA) sur prothèse montre des taux de rémission comparables au ceux en deux temps (85–92 %), mais la durée de l’antibiothérapie n’est pas encore bien déterminée. L’étude examinait l’efficacité de six semaines d’antibiothérapie dans les IOA sur prothèse après RTP en un temps.

Patientes et méthodes

Étude observationnelle rétrospective réalisée dans le service d’orthopédie de l’hôpital Cochin, Paris, entre le 1er janvier 2010 et le 31 décembre 2015. Étaient inclus les patients ayant une IOA sur prothèse, microbiologiquement prouvée, ayant bénéficier d’une RPT et d’une antibiothérapie pour 6 semaines (±1 semaine). Les variables catégorielles et continues étaient comparés respectivement par les tests de Pearson-χ2 et de Wilcoxon.

Résultats

Cinquante patients porteurs d’une IOA sur prothèse (hanche=42, genou=8) traités par remplacement en un temps ont été inclus. L’âge médian était 69,3 ans (IQR : 24,5–97,4). Le délai moyen de survenue de l’infection était de 36 mois (IQR 1–216). Les principales bactéries identifiées étaient Staphylococcus spp. (58 %), Cutibacterium acnes (38 %), bacilles Gram-négatif (12 %). Il s’agissait d’infections polymicrobiennes dans 24 % des cas. Les antibiotiques étaient administrés par voie intraveineuse pendant en médiane 11jours (IQR 4–45) poursuivis par voie orale chez 46 (92 %) patients. Le suivi médian était 32 mois (IQR 12–101). Le taux de rémission était de 90 %.

Conclusion

Six semaines d’antibiothérapie dans les IOA sur prothèse après RTP en un temps ont un taux de rémission satisfaisant dans cette étude ouverte.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Replacement arthroplasty, One-stage replacement, Periprosthetic joint infections

Mots clés : Reprise totale de prothèse, Reprise en un temps, Infections ostéoarticulaires sur prothèse


Mappa


© 2020  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 50 - N° 7

P. 567-574 - Ottobre 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Ebola virus disease in children in Conakry and Coyah Ebola treatment centers and risk factors associated with death
  • M.S. Sow, D.C. Sow, M.L. Diallo, D. Kassé, K. Sylla, A. Camara, S.D. Djiro, M.O.S. Diallo, E.I. Bah, I. Bah, M.P. Diallo
| Articolo seguente Articolo seguente
  • E-health. Patterns of use and perceived benefits and barriers among people living with HIV and their physicians. Part 1: Information retrieval on the Internet and social networks
  • C. Jacomet, P. Bastiani, J. Prouteau, C. Lambert, F. Linard, R. Ologeanu-Taddei, P. Dellamonica

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.